The Complex Movement Disorders program at the Royal Children’s Hospital commenced in 1997 and has evolved since then. It is currently funded by RCH Foundation and the fundraising efforts of A/Prof Andrew Kornberg’s Fly for the Kids event in 2017. The program allows coordinated multidisciplinary assessment and management of children with movement disorders and associated neurodevelopmental comorbidities.
Advances in health and medical research are accelerating our understanding of disease mechanisms, and leading to new preventative interventions, diagnostic tools and novel therapeutic approaches that are transforming clinical care. Hence, there is an increasing need to better embed clinical research into clinical care delivered at the RCH and to support the development of individuals who are fluent in both clinical care and research.
Never in the field of health was so much learned by so many in so few months. This, the opening Grand Round for 2021 will recap the lessons from last year, take stock of where we are in February 2021, describe the complex situation with vaccines, and look to what the year might hold for the pandemic and children in Australia and countries around the world. Topics will include: Why is COVID-19 less severe in children? What is the role of schools in transmission and what is the impact of new variants? Vaccines: who, when and how? The indirect effects of Covid: poverty and malnutrition, measles, loss of education, and child marriage.
RCH is excited to be celebrating Allied Health Professionals Day on 14 October 2020. Allied Health Professionals Day first began in the UK in 2018 and has since become an international event to recognise and celebrate the Allied Health Professional community.
Vernon Collins Oration 2020
Championing child rights amidst the chaos of COVID-19
Professor Elizabeth Elliott, AM
There has in recent years been a rapid increase in the number and complexity of clinical trials and novel therapies for neurogenetic conditions. Many of these conditions are individually rare, but their impact upon affected children and their families may be very severe. While the increasing awareness and availability of new treatments brings great hope and excitement for all involved in care of these children, it also presents significant challenges for clinicians and for patients and their families.
Chimeric Antigen Receptor (CAR) T cells have revolutionised treatment for patients with acute lymphoblastic leukaemia (ALL) where standard therapies have failed. We reflect on our first 12 months as the first national paediatric referral centre providing CAR T cell treatment to children with relapsed or refractory ALL from Australia and New Zealand, and highlight the collective efforts and lessons for the hospital-wide CAR T cell team.
Blood-clotting complications are rapidly emerging as a significant part of the pathogenesis of COVID-19. There are reports of otherwise well people with COVID-10 having strokes, pulmonary emboli and heart attacks, and children with inflammation of their blood vessels. In recent weeks series of cases of a multi-system inflammatory condition, some resembling Kawasaki disease, have been reported in children in Europe, UK and USA.
Several Grand Rounds in 2020, the 150th year of the Children’s Hospital, will highlight the development of services, some looking back and looking forward. This opening Grand Round will review the innovations in diabetes, adolescent health, and links between the hospital and the community. Dr John Court was a paediatrician who had a key role in service development at The Royal Children’s Hospital from the late 1950’s to the 1990’s including research and clinical care.
Seizures are more common in the neonatal period than at any other time of life. Recognition of seizures in the NICU has changed in recent years with the introduction of bedside EEG tools. Increased recognition has raised the sceptre of whether all subclinical seizures need treatment with anticonvulsants.
